<DOC>
	<DOCNO>NCT00705003</DOCNO>
	<brief_summary>The primary objective study evaluate synergistic effect combination product , consist drug BCI-024 ( buspirone ) drug BCI-049 ( melatonin ) , reduce symptom depression patient Major Depressive Disorder . The safety tolerability combination product also evaluate measured adverse event vital sign .</brief_summary>
	<brief_title>Efficacy Safety Study Combination Product Drug : BCI-024 ( Buspirone ) Drug : BCI-049 ( Melatonin ) Treat Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description>Approximately 120 adult outpatient meet study 's inclusion exclusion criterion randomize study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>Subjects male female subject age 18 65 meeting Diagnostic Statistical Manual Mental DisordersIVText Revision ( DSMIVTR ) criteria Major Depressive Disorder Quick Inventory Depressive Symptomatology16 Item Self Report ( QIDSSR16 ) score &gt; 14 Screening Baseline Visits . Female subject must stable medically reliable form birth control , must agree continue use birth control study , must negative urine pregnancy test Screening Visit . Subjects psychiatric AxisI disorder principal diagnosis within 6 month screen subject history obsessive compulsive disorder , psychotic disorder , bipolar disorder , mental retardation time eligible study . Subjects pose suicidal risk history eat disorder substance dependence within 6 month screen , history substance abuse within 3 month screen also ineligible . Subjects clinically significant abnormality Screening Baseline assessment , include laboratory test , exclude . Subjects know intolerance either buspirone melatonin exclude , subject clinically significant medical psychiatric condition might detrimental subject participate study . Subjects use selective serotonin reuptake inhibitor ( SSRIs ) within 2 week Screening ( within 4 week fluoxetine ) exclude subject require concomitant use antipsychotic anxiolytic medication drug know psychotropic property . Concomitant medication exclude protocol take chronically must stable dosage least 4 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>depression</keyword>
</DOC>